Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Vertex Pharmaceuticals Inc / Ma (VRTX) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Vertex Pharmaceuticals Inc / Ma. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 875320.
Total stock buying since 2014: $14,032,945.
Total stock sales since 2014: $1,196,910,074.
Total stock option exercises since 2014: $345,948,365.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 15,000 | $5,843,150 | 36,186 | $17,560,365 | 0 | $0 |
| 2024 | 0 | $0 | 148,610 | $67,869,390 | 14,306 | $1,623,040 |
| 2023 | 0 | $0 | 293,658 | $101,547,730 | 106,203 | $13,301,242 |
| 2022 | 0 | $0 | 299,056 | $84,212,962 | 129,539 | $14,304,907 |
| 2021 | 25,000 | $4,926,050 | 80,192 | $17,017,085 | 3,884 | $336,043 |
| 2020 | 15,000 | $3,263,745 | 823,381 | $212,996,253 | 593,830 | $68,989,498 |
| 2019 | 0 | $0 | 749,106 | $142,436,412 | 640,272 | $64,836,003 |
| 2018 | 0 | $0 | 677,893 | $111,360,024 | 569,594 | $48,688,330 |
| 2017 | 0 | $0 | 1,829,749 | $255,631,975 | 1,303,112 | $81,084,922 |
| 2016 | 0 | $0 | 425,204 | $38,606,160 | 329,295 | $11,861,367 |
| 2015 | 0 | $0 | 1,169,000 | $146,404,893 | 1,011,116 | $40,701,778 |
| 2014 | 0 | $0 | 10,500 | $1,266,825 | 10,500 | $221,235 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-05-15 | Tatsis Ourania (EVP, Chief Regulatory Officer) | Sale | 120 | 283.42 | 34,010 |
| 2020-05-15 | Kewalramani Reshma (CEO & President) | Sale | 99 | 282.12 | 27,930 |
| 2020-05-15 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Sale | 68 | 281.77 | 19,160 |
| 2020-05-15 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Sale | 113 | 283.49 | 32,034 |
| 2020-05-15 | Altshuler David (EVP, Global Research and CSO) | Sale | 82 | 282.34 | 23,152 |
| 2020-05-15 | Silva Paul M (SVP & Controller) | Sale | 151 | 282.97 | 42,728 |
| 2020-05-15 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 58 | 282.19 | 16,366 |
| 2020-05-12 | Altshuler David (EVP, Global Research and CSO) | Sale | 1,304 | 287.33 | 374,678 |
| 2020-05-12 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 1,304 | 187.53 | 244,539 |
| 2020-05-12 | Leiden Jeffrey M (Executive Chairman) | Sale | 94,370 | 283.07 | 26,713,127 |
| 2020-05-12 | Leiden Jeffrey M (Executive Chairman) | Option Ex | 88,532 | 132.75 | 11,753,065 |
| 2020-05-11 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Sale | 1,304 | 286.00 | 372,944 |
| 2020-05-11 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Option Ex | 1,304 | 187.53 | 244,539 |
| 2020-05-11 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 10,665 | 282.05 | 3,008,052 |
| 2020-05-11 | Sachdev Amit (EVP, Chief Patient Officer) | Option Ex | 10,665 | 131.89 | 1,406,606 |
| 2020-05-07 | Leiden Jeffrey M (Executive Chairman) | Sale | 94,369 | 270.02 | 25,481,517 |
| 2020-05-07 | Leiden Jeffrey M (Executive Chairman) | Option Ex | 88,534 | 132.75 | 11,753,331 |
| 2020-05-07 | Sachs Bruce I (Director) | Sale | 45,000 | 270.04 | 12,151,935 |
| 2020-05-07 | Sachs Bruce I (Director) | Option Ex | 45,000 | 70.55 | 3,174,525 |
| 2020-05-06 | Tatsis Ourania (EVP, Chief Regulatory Officer) | Sale | 966 | 272.28 | 263,019 |
| 2020-05-06 | Tatsis Ourania (EVP, Chief Regulatory Officer) | Option Ex | 966 | 171.55 | 165,717 |
| 2020-05-06 | Kewalramani Reshma (CEO & President) | Sale | 2,074 | 272.85 | 565,890 |
| 2020-05-06 | Kewalramani Reshma (CEO & President) | Option Ex | 2,074 | 171.55 | 355,794 |
| 2020-05-06 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Sale | 1,222 | 272.70 | 333,236 |
| 2020-05-06 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Option Ex | 1,222 | 155.57 | 190,106 |
| 2020-05-06 | Altshuler David (EVP, Global Research and CSO) | Sale | 1,222 | 272.47 | 332,955 |
| 2020-05-06 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 1,222 | 155.57 | 190,106 |
| 2020-05-06 | Silva Paul M (SVP & Controller) | Sale | 1,076 | 272.57 | 293,287 |
| 2020-05-06 | Silva Paul M (SVP & Controller) | Option Ex | 1,076 | 171.55 | 184,587 |
| 2020-05-06 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 669 | 275.28 | 184,162 |
| 2020-05-06 | Sachdev Amit (EVP, Chief Patient Officer) | Option Ex | 669 | 131.89 | 88,234 |
| 2020-05-05 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 13,356 | 269.92 | 3,604,998 |
| 2020-05-05 | Sachdev Amit (EVP, Chief Patient Officer) | Option Ex | 13,356 | 131.89 | 1,761,522 |
| 2020-05-05 | Leiden Jeffrey M (Executive Chairman) | Sale | 94,372 | 269.77 | 25,458,640 |
| 2020-05-05 | Leiden Jeffrey M (Executive Chairman) | Option Ex | 88,537 | 132.75 | 11,753,729 |
| 2020-05-04 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Sale | 2,330 | 261.57 | 609,462 |
| 2020-05-04 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Option Ex | 2,330 | 86.52 | 201,591 |
| 2020-05-04 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Sale | 1,553 | 261.69 | 406,404 |
| 2020-05-04 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Option Ex | 1,553 | 86.52 | 134,365 |
| 2020-05-04 | Altshuler David (EVP, Global Research and CSO) | Sale | 2,330 | 261.58 | 609,476 |
| 2020-05-04 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 2,330 | 86.52 | 201,591 |
| 2020-05-04 | Silva Paul M (SVP & Controller) | Sale | 809 | 261.66 | 211,684 |
| 2020-05-04 | Silva Paul M (SVP & Controller) | Option Ex | 809 | 86.52 | 69,994 |
| 2020-05-04 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 43,752 | 261.65 | 11,447,842 |
| 2020-05-04 | Sachdev Amit (EVP, Chief Patient Officer) | Option Ex | 43,752 | 109.18 | 4,776,974 |
| 2020-04-29 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Sale | 2,125 | 254.75 | 541,343 |
| 2020-04-29 | Parini Michael (EVP, Chief Adm, Leg & BD Officer) | Option Ex | 2,125 | 90.29 | 191,866 |
| 2020-04-28 | Lee Yuchun (Director) | Sale | 1,125 | 258.32 | 290,614 |
| 2020-04-28 | Lee Yuchun (Director) | Option Ex | 1,125 | 57.27 | 64,428 |
| 2020-04-27 | Lee Yuchun (Director) | Sale | 2,000 | 271.26 | 542,512 |
| 2020-04-27 | Lee Yuchun (Director) | Option Ex | 2,000 | 57.27 | 114,540 |
| 2020-04-24 | Lee Yuchun (Director) | Sale | 2,000 | 268.78 | 537,560 |
| 2020-04-24 | Lee Yuchun (Director) | Option Ex | 2,000 | 57.27 | 114,540 |
| 2020-04-23 | Lee Yuchun (Director) | Sale | 2,000 | 272.41 | 544,818 |
| 2020-04-23 | Lee Yuchun (Director) | Option Ex | 2,000 | 57.27 | 114,540 |
| 2020-04-22 | Lee Yuchun (Director) | Sale | 2,000 | 267.86 | 535,724 |
| 2020-04-22 | Lee Yuchun (Director) | Option Ex | 2,000 | 57.27 | 114,540 |
| 2020-04-21 | Lee Yuchun (Director) | Sale | 2,000 | 267.65 | 535,298 |
| 2020-04-21 | Lee Yuchun (Director) | Option Ex | 2,000 | 57.27 | 114,540 |
| 2020-04-20 | Lee Yuchun (Director) | Sale | 2,000 | 272.44 | 544,876 |
| 2020-04-20 | Lee Yuchun (Director) | Option Ex | 2,000 | 57.27 | 114,540 |
| 2020-04-13 | Silva Paul M (SVP & Controller) | Sale | 859 | 248.07 | 213,089 |
| 2020-04-13 | Silva Paul M (SVP & Controller) | Option Ex | 859 | 90.29 | 77,559 |
| 2020-04-06 | Silva Paul M (SVP & Controller) | Sale | 4,891 | 255.57 | 1,249,992 |
| 2020-04-06 | Silva Paul M (SVP & Controller) | Option Ex | 4,891 | 155.57 | 760,892 |
| 2020-02-25 | Tatsis Ourania (SVP, CRO) | Sale | 1,296 | 233.57 | 302,713 |
| 2020-02-25 | Kewalramani Reshma (EVP and CMO) | Sale | 3,634 | 234.60 | 852,554 |
| 2020-02-25 | Parini Michael (EVP, CL&AO) | Sale | 3,028 | 233.99 | 708,506 |
| 2020-02-25 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Sale | 3,634 | 234.22 | 851,159 |
| 2020-02-25 | Altshuler David (EVP, Global Research and CSO) | Sale | 3,028 | 234.03 | 708,630 |
| 2020-02-25 | Silva Paul M (SVP & Controller) | Sale | 1,080 | 234.07 | 252,792 |
| 2020-02-25 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 3,376 | 234.01 | 790,004 |
| 2020-02-25 | Leiden Jeffrey M (CEO & President) | Sale | 10,550 | 233.73 | 2,465,893 |
| 2020-02-18 | Tatsis Ourania (SVP, CRO) | Sale | 1,279 | 243.82 | 311,850 |
| 2020-02-18 | Kewalramani Reshma (EVP and CMO) | Sale | 1,183 | 243.76 | 288,363 |
| 2020-02-18 | Parini Michael (EVP, CL&AO) | Sale | 3,128 | 243.63 | 762,068 |
| 2020-02-18 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Sale | 3,128 | 243.91 | 762,950 |
| 2020-02-18 | Altshuler David (EVP, Global Research and CSO) | Sale | 3,128 | 243.70 | 762,306 |
| 2020-02-18 | Silva Paul M (SVP & Controller) | Sale | 1,564 | 243.87 | 381,409 |
| 2020-02-18 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 3,489 | 243.99 | 851,274 |
| 2020-02-18 | Leiden Jeffrey M (CEO & President) | Sale | 11,685 | 243.71 | 2,847,798 |
| 2020-02-11 | Parini Michael (EVP, CL&AO) | Sale | 16,882 | 246.06 | 4,154,018 |
| 2020-02-11 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Sale | 11,286 | 246.33 | 2,780,057 |
| 2020-02-11 | Altshuler David (EVP, Global Research and CSO) | Sale | 17,032 | 246.17 | 4,192,767 |
| 2020-02-11 | Silva Paul M (SVP & Controller) | Sale | 5,862 | 245.83 | 1,441,055 |
| 2020-02-11 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 13,070 | 246.36 | 3,219,925 |
| 2020-02-11 | Leiden Jeffrey M (CEO & President) | Sale | 47,523 | 245.92 | 11,686,761 |
| 2020-02-10 | Lee Yuchun (Director) | Sale | 1,181 | 242.57 | 286,475 |
| 2020-02-10 | Lee Yuchun (Director) | Option Ex | 1,181 | 57.27 | 67,635 |
| 2020-02-07 | Lee Yuchun (Director) | Sale | 2,000 | 237.42 | 474,840 |
| 2020-02-07 | Lee Yuchun (Director) | Option Ex | 2,000 | 57.27 | 114,540 |
| 2020-02-06 | Tatsis Ourania (SVP, CRO) | Sale | 967 | 240.41 | 232,471 |
| 2020-02-06 | Tatsis Ourania (SVP, CRO) | Option Ex | 967 | 171.55 | 165,888 |
| 2020-02-06 | Kewalramani Reshma (EVP and CMO) | Sale | 2,074 | 240.42 | 498,626 |
| 2020-02-06 | Kewalramani Reshma (EVP and CMO) | Option Ex | 2,074 | 171.55 | 355,794 |
| 2020-02-06 | Parini Michael (EVP, CL&AO) | Sale | 2,526 | 240.40 | 607,257 |
| 2020-02-06 | Parini Michael (EVP, CL&AO) | Option Ex | 2,526 | 171.55 | 433,335 |
| 2020-02-06 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Sale | 2,787 | 240.45 | 670,139 |
| 2020-02-06 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Option Ex | 2,787 | 171.55 | 478,109 |
| 2020-02-06 | Altshuler David (EVP, Global Research and CSO) | Sale | 2,526 | 240.41 | 607,288 |
| 2020-02-06 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 2,526 | 171.55 | 433,335 |
| 2020-02-06 | Silva Paul M (SVP & Controller) | Sale | 466 | 240.55 | 112,097 |
| 2020-02-06 | Silva Paul M (SVP & Controller) | Option Ex | 466 | 187.53 | 87,388 |
| 2020-02-06 | Lee Yuchun (Director) | Sale | 2,000 | 240.68 | 481,360 |
| 2020-02-06 | Lee Yuchun (Director) | Option Ex | 2,000 | 57.27 | 114,540 |
| 2020-02-05 | Lee Yuchun (Director) | Sale | 2,000 | 242.38 | 484,766 |
| 2020-02-05 | Lee Yuchun (Director) | Option Ex | 2,000 | 57.27 | 114,540 |
| 2020-02-04 | Lee Yuchun (Director) | Sale | 2,000 | 238.01 | 476,030 |
| 2020-02-04 | Lee Yuchun (Director) | Option Ex | 3,028 | 57.27 | 173,413 |
| 2020-02-03 | Parini Michael (EVP, CL&AO) | Sale | 4,436 | 231.03 | 1,024,857 |
| 2020-02-03 | Parini Michael (EVP, CL&AO) | Option Ex | 2,330 | 86.52 | 201,591 |
| 2020-02-03 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Sale | 3,710 | 230.93 | 856,735 |
| 2020-02-03 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Option Ex | 3,710 | 88.78 | 329,392 |
| 2020-02-03 | Altshuler David (EVP, Global Research and CSO) | Sale | 4,126 | 231.12 | 953,621 |
| 2020-02-03 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 4,126 | 88.78 | 366,326 |
| 2020-02-03 | Silva Paul M (SVP & Controller) | Sale | 2,099 | 230.89 | 484,629 |
| 2020-02-03 | Silva Paul M (SVP & Controller) | Option Ex | 2,099 | 88.78 | 186,359 |
| 2020-02-03 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 4,097 | 231.00 | 946,407 |
| 2020-02-03 | Sachdev Amit (EVP, Chief Patient Officer) | Option Ex | 4,097 | 88.78 | 363,752 |
| 2020-02-03 | Lee Yuchun (Director) | Sale | 2,000 | 231.12 | 462,236 |
| 2020-01-31 | Parini Michael (EVP, CL&AO) | Sale | 3,909 | 238.65 | 932,882 |
| 2020-01-31 | Parini Michael (EVP, CL&AO) | Option Ex | 3,909 | 187.53 | 733,054 |
| 2020-01-31 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Sale | 4,692 | 238.65 | 1,119,745 |
| 2020-01-31 | Arbuckle Stuart A (EVP, Chief Commercial Officer) | Option Ex | 4,692 | 187.53 | 879,890 |
| 2020-01-31 | Silva Paul M (SVP & Controller) | Sale | 1,396 | 238.65 | 333,155 |
| 2020-01-31 | Silva Paul M (SVP & Controller) | Option Ex | 1,396 | 187.53 | 261,791 |
| 2020-01-31 | Lee Yuchun (Director) | Sale | 2,000 | 228.46 | 456,922 |
| 2020-01-31 | Sachs Bruce I (Director) | Sale | 20,000 | 229.48 | 4,589,680 |
| 2020-01-31 | Sachs Bruce I (Director) | Option Ex | 20,000 | 53.85 | 1,077,000 |
| 2020-01-22 | Parini Michael (EVP, CL&AO) | Sale | 1 | 237.50 | 237 |
| 2020-01-22 | Parini Michael (EVP, CL&AO) | Option Ex | 1 | 187.53 | 187 |
| 2020-01-16 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 5,000 | 235.00 | 1,175,000 |
| 2020-01-16 | Sachdev Amit (EVP, Chief Patient Officer) | Option Ex | 5,000 | 109.14 | 545,700 |
| 2020-01-13 | Parini Michael (EVP, CL&AO) | Sale | 2,125 | 227.06 | 482,502 |
| 2020-01-13 | Parini Michael (EVP, CL&AO) | Option Ex | 2,125 | 90.29 | 191,866 |
| 2020-01-13 | Silva Paul M (SVP & Controller) | Sale | 860 | 229.38 | 197,266 |
| 2020-01-13 | Silva Paul M (SVP & Controller) | Option Ex | 860 | 90.29 | 77,649 |
| 2020-01-08 | Tatsis Ourania (SVP, CRO) | Sale | 1,675 | 227.53 | 381,112 |
| 2020-01-08 | Tatsis Ourania (SVP, CRO) | Option Ex | 1,675 | 187.53 | 314,112 |
| 2020-01-08 | Silva Paul M (SVP & Controller) | Sale | 13,750 | 231.89 | 3,188,487 |
| 2020-01-08 | Silva Paul M (SVP & Controller) | Option Ex | 13,750 | 131.89 | 1,813,487 |
| 2020-01-08 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 5,000 | 230.00 | 1,150,000 |
| 2020-01-08 | Sachdev Amit (EVP, Chief Patient Officer) | Option Ex | 5,000 | 109.14 | 545,700 |
| 2020-01-06 | Parini Michael (EVP, CL&AO) | Sale | 4,250 | 221.91 | 943,138 |
| 2020-01-06 | Parini Michael (EVP, CL&AO) | Option Ex | 4,250 | 122.45 | 520,412 |
| 2020-01-02 | Silva Paul M (SVP & Controller) | Sale | 25,630 | 218.96 | 5,611,816 |
| 2020-01-02 | Silva Paul M (SVP & Controller) | Option Ex | 25,630 | 94.25 | 2,415,627 |
| 2020-01-02 | Young William D (Director) | Sale | 20,000 | 218.97 | 4,379,500 |
| 2020-01-02 | Young William D (Director) | Option Ex | 20,000 | 72.14 | 1,442,800 |
| 2019-12-30 | Young William D (Director) | Sale | 30,000 | 219.60 | 6,587,940 |
Insider trading activities including stock purchases, stock sales, and option exercises of VRTX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Vertex Pharmaceuticals Inc / Ma (symbol VRTX, CIK number 875320) see the Securities and Exchange Commission (SEC) website.